Growth hormone response in man to L-692,429, a novel nonpeptide mimic of growth hormone-releasing peptide-6

• Published in: The journal of clinical endocrinology and metabolism Vol. 77; no. 5; p. 1393
• Main Authors: Gertz, B J, Barrett, J S, Eisenhandler, R, Krupa, D A, Wittreich, J M, Seibold, J R, Schneider, S H
• Format: Journal Article
• Language: English
• Published: United States 01.11.1993
• Subjects: Adolescent; Adult; Benzazepines - adverse effects; Benzazepines - blood; Benzazepines - pharmacology; Double-Blind Method; Growth Hormone - blood; Growth Hormone-Releasing Hormone - pharmacology; Hormones - blood; Humans; Hydrocortisone - blood; Male; Oligopeptides - pharmacology; Osmolar Concentration; Placebos; Prolactin - blood; Tetrazoles - adverse effects; Tetrazoles - blood; Tetrazoles - pharmacology
• ISSN: 0021-972X; 1945-7197
• DOI: 10.1210/jc.77.5.1393

L-692,429, a substituted benzolactam, is a novel nonpeptide mimic of the GH secretagogue, GH-releasing peptide-6. The safety and GH secretory activity of L-692,429 (0.001-1.0 mg/kg, i.v.) were investigated in 24 healthy nonobese young (18-26 yr old) male volunteers who demonstrated a GH response of 7 micrograms/L or more after 1 microgram/kg, i.v. GH-releasing hormone [GH-releasing hormone-(1-29)NH2]. L-692,429 was administered as a 15-min iv infusion in an incremental dose, double blind, placebo-controlled, alternating panel fashion to 3 panels of 8 subjects each. Dose-dependent GH secretion was observed with a threshold dose of 0.05 mg/kg (4 of 6 subjects responded with peak GH > 7 micrograms/L), and 0.2 mg/kg produced a response in all 14 subjects tested (mean +/- SE peak GH, 41.0 +/- 6.3 micrograms/L). The maximum dose of 1.0 mg/kg L-692,429 resulted in a pronounced GH response (peak GH, 82.5 +/- 14.9 micrograms/L; n = 8). The GH peak was seen 30-45 min after initiation of the infusion. Small transient increases in cortical and PRL were observed (increases in cortical averaged 182.1 +/- 33.1 nmol/L and peak PRL was 21 +/- 2.6 micrograms/L after 1.0 mg/kg L-692,429, respectively), whereas no significant changes occurred in LH, FSH, TSH, insulin, or glucose concentrations. Plasma pharmacokinetic analysis revealed dose-related increases in plasma concentrations of L-692,429 and a half-life of 3.8 +/- 0.2 (+/- SE) h, a plasma clearance of 214 +/- 67 mL/min, and a steady state volume of distribution of 14.2 +/- 4.8 L. Facial flushing or a warm sensation were reported in 4 subjects, primarily at dose levels of 0.2 mg/kg L-692,429 or more, but no other clinical or laboratory adverse experiences appeared related to drug treatment. L-692,429, synthesized as a specific nonpeptide mimic of GH-releasing peptide-6, is thus a well tolerated, highly effective, and selective GH secretagogue in man.